Novo Nordisk sees solid Q1 results, major GLP-1 growth potential, and limited downside despite guidance cut and rising risks.

Novo Nordisk NVO generates most of its revenues from the sales of its blockbuster GLP-1 injections, Ozempic for type II ...

Novo Nordisk Foundation & Denmark invest €80M in a Microsoft-powered quantum computer to boost Nordic tech innovation.

The Danish government and the foundation behind Novo Nordisk A/S will invest €80 million ($93 million) in a Microsoft-powered ...

Eli Lilly (LLY 0.40%) and Novo Nordisk (NVO 1.97%) are two phenomenal growth stocks that investors probably can't go wrong ...

Clever Culture’s APAS is now on trial with Novo Nordisk, and if it delivers, this one machine could unlock a global pharma ...

Key Points Hims & Hers Health is entering the Canadian market.The company will offer a generic version of semaglutide in the ...

Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader in Internet healthcare solutions, signed a Memorandum of Understanding with Novo Nordisk, a leading global healthcare company, at the ...

Novo Nordisk A/S (NYSE: NVO) is one of the high-margin pharma stocks to buy now. Berenberg has reaffirmed its Hold rating on ...

Novo Nordisk (($DE:NOVA)) announced an update on their ongoing clinical study. Novo Nordisk has completed a 40-week clinical study titled ‘A ...

Novo Nordisk (NVO) closed the most recent trading day at $65.29, moving 2.61% from the previous trading session.

The partnership helps Novo capture patients who have been using compounded versions of the medicine, while allowing ...